Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,573.66
(
0.13%
)
US TECH 100
29,463.20
(
0.13%
)
Dow Jones
50,978.62
(
0.61%
)
Brent Oil
90.91
(
-1.38%
)
Bitcoin
73,917.72
(
0.51%
)
News Focus
News Focus
Post# of 257656
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123036
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tinkershaw post# 62833

Thursday, 05/22/2008 12:25:48 AM

Thursday, May 22, 2008 12:25:48 AM

Post# of 257656
>SGP VRTX – Could very well be that the FDA required 28 week treatment [in the SPRINT-2 treatment-naïve trial] and it will juxtapose against 48 week treatment given the present data out of boceprevir.<

Regardless of whether the FDA required a 28-week arm in SPRINT-2, it clearly benefits SGP to include such an arm.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today